This will be a trial to test the clinical and radiographic efficacy of monthly pulse infusion therapy in beta-interferon-resistant active MS patients. While beta-interferon medications have been shown to reduce disease activity in relapsing remitting MS patients, many patients continue to have active disease despite being on these medications. There is evidence that treatment of these patients with pulse methylprednisolone, pulse mitoxantrone or pulse cyclophosphamide may effectively reduce disease activity in these patients and potentially allow them to be stable maintained on beta-interferon therapy thereafter. This study is designed to randomize beta-interferon non-responsive patients for six months of treatment to either monthly intravenous pulse cyclophosphamide plus methylprednisolone or monthly intravenous pulse mitoxantrone plus methylprednisolone or monthly intravenous methylprednisolone alone. Patients will be maintained on beta-interferon and followed over 24 months. 20 patients will be enrolled per arm. MRI number of gadolinium enhancing lesions and T2 lesion volume will be the principal outcome measures while clinical scores and immunologic studies will be secondary outcome measures. Measurement of adverse events will also be an important component. Thus far the applicant's research has focused on immunologic studies in MS with the goal of understanding the mechanism of action of drugs used to treat the disease. We have found that the treatment of MS patients with some of these agents results in a number of changes, notably increases of IL-4 secretion associated with eosinophilia and decreases in IL-12.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
1K23NS002117-01
Application #
2897415
Study Section
NST-2 Subcommittee (NST)
Program Officer
Kerza-Kwiatecki, a P
Project Start
1999-07-05
Project End
2004-06-30
Budget Start
1999-07-05
Budget End
2000-06-30
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Kodumuri, Nishanth; Giamberardino, Lauren; Hinderliter, Alan et al. (2016) Association of Dietary Factors with Progression of AA in Stroke/TIA Patients. J Neurol Disord 4:
Sen, Souvik; Hinderliter, Alan; Sen, Pranab K et al. (2007) Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. Circulation 116:928-35
Sen, Souvik; Hinderliter, Alan; Sen, Pranab K et al. (2007) Association of leukocyte count with progression of aortic atheroma in stroke/transient ischemic attack patients. Stroke 38:2900-5
Smith, D R; Weinstock-Guttman, B; Cohen, J A et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11:573-82
Sen, Souvik; Lima, Joao A C; Oppenheimer, Stephen M (2004) Changes in cardiac thrombus status after cerebral ischemia. Cerebrovasc Dis 17:175-81
Sen, Souvik; Oppenheimer, Stephen M; Lima, Joao et al. (2002) Risk factors for progression of aortic atheroma in stroke and transient ischemic attack patients. Stroke 33:930-5